

# FDA Dramatically Narrows Use of Johnson & Johnson COVID-19 Vaccine

The single-shot Covid-19 vaccine will now only be available for adults who cannot or will not receive an mRNA vaccine.

By [Katherine Ellen Foley](#) and [Lauren Gardner](#)

Global Research, May 06, 2022

[Politico](#) 5 May 2022

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the “Translate Website” drop down menu on the top banner of our home page (Desktop version).

To receive Global Research’s Daily Newsletter (selected articles), [click here](#).

Visit and follow us on [Instagram](#), [Twitter](#) and [Facebook](#). Feel free to repost and share widely Global Research articles.

\*\*\*

*The Food and Drug Administration has restricted the use of the Johnson & Johnson Covid-19 vaccine to adults who are unable or unwilling to get the Pfizer-BioNTech or Moderna mRNA shots.*

The decision comes after the agency completed an updated risk analysis of developing thrombosis with thrombocytopenia syndrome, or TTS, a rare and possibly fatal combination of blood clots and low platelet counts one to two weeks after receiving the vaccine, the agency said Thursday.

Given the severity and urgency of the syndrome, and the availability of other Covid-19 vaccines, FDA decided that the benefits of Covid-19 protection from the Johnson & Johnson vaccine outweigh the risk of TTS only for those who cannot or will not receive other forms of vaccination.

“Our action reflects our updated analysis of the risk of [thrombosis with thrombocytopenia syndrome] following administration of this vaccine and limits the use of the vaccine to certain individuals,” Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, [said in a statement](#). “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community ... The agency will continue to monitor the safety of the Janssen COVID-19 Vaccine and all other vaccines.”

Johnson & Johnson said in a statement it will continue to work with regulators worldwide to ensure consumers “are warned and fully informed about reports of TTS.”

[Click here to read the full article.](#)

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, Twitter and Facebook. Feel free to repost and share widely Global Research articles.

*Featured image is from Children's Health Defense*

The original source of this article is [Politico](#)

Copyright © [Katherine Ellen Foley](#) and [Lauren Gardner](#), [Politico](#), 2022

---

[\*\*Comment on Global Research Articles on our Facebook page\*\*](#)

[\*\*Become a Member of Global Research\*\*](#)

Articles by: [Katherine Ellen Foley](#) and [Lauren Gardner](#)

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)  
[www.globalresearch.ca](http://www.globalresearch.ca) contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [publications@globalresearch.ca](mailto:publications@globalresearch.ca)